Pfizer Bold 2024 Forecast: A New Era Dawns
Pfizer Inc. has provided its financial forecast guidance for the full year of 2024, accounting for the anticipated impact...
ACRO Unveils Power Squad for 2024: Meet the New Faces
The Association of Clinical Research Organizations (ACRO) announced the election of Peyton Howell, Chief Operating & Growth Officer at...
Miracle CAR T-Cell Hope from Gilead for Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), has presented encouraging data from various studies on the CAR T-cell therapies Tecartus®...
Mooresville Locals Breathe Easy with Sanofi COPD Study
A new clinical trial, known as the AERIFY-2 study, is underway in Mooresville, N.C., focusing on chronic obstructive pulmonary...
Pfizer & Seagen Merge: A Monumental, Surprising Union
Pfizer Inc. has reached a significant milestone in its pending acquisition of Seagen Inc., with all required regulatory approvals...
Merck & Moderna Blaze Trail with New Cancer Vaccine Trial
Merck, and Moderna, Inc., have launched INTerpath-002, a pivotal Phase 3 randomized clinical trial for a cancer vaccine. The...
Sanofi Venetoclax: Breakthrough NK Cell Therapy Stuns at ASH 2023
Innate Pharma SA, in collaboration with Sanofi, shared updated efficacy and safety results from a Phase 1/2 dose-escalation study...
Merck, Eisai’s Shock: KEYTRUDA-LENVIMA Fail
Merck and Eisai have reported that the Phase 3 LEAP-001 trial for the first-line treatment of patients with advanced...
Pfizer Unveils Marstacimab: Hemophilia’s New Hope
Pfizer Inc. has shared promising results from its pivotal Phase 3 BASIS clinical trial of marstacimab, a potential new...
Merck Evobrutinib Fails in Trials: A Devastating Outcome for MS
Merck KGaA, a renowned science and technology company, has announced the results of its two Phase III EVOLUTION clinical...